- Home
- KNOP vs HUMA Comparison
KNOP vs HUMA Comparison
Compare KNOP & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNOP | HUMA |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.6M | 236.0M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | KNOP | HUMA |
|---|---|---|
| Price | $10.74 | $1.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | N/A | ★ $10.13 |
| AVG Volume (30 Days) | 141.2K | ★ 4.3M |
| Earning Date | 12-04-2025 | 11-12-2025 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $352,712,000.00 | $1,571,000.00 |
| Revenue This Year | $13.56 | N/A |
| Revenue Next Year | $2.42 | $731.05 |
| P/E Ratio | $9.08 | ★ N/A |
| Revenue Growth | ★ 17.65 | N/A |
| 52 Week Low | $5.28 | $1.09 |
| 52 Week High | $10.99 | $6.77 |
Technical Indicators
Market Signals| Indicator | KNOP | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 66.95 | 47.73 |
| Support Level | $10.41 | $1.21 |
| Resistance Level | $10.85 | $1.32 |
| Average True Range (ATR) | 0.22 | 0.07 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 79.57 | 55.88 |
Price Performance
Historical ComparisonAbout KNOP KNOT Offshore Partners LP
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.